ms TRICIA BROOKS

General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).

General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program; H.R.9599 Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act)

General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).

Pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.

Issues related to pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.

General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).

General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).

General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.

Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Congressionally Directed Medical Research Program (malaria); Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; PBM reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.

General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Proposed Rebate Rule.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.

Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.

Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.

Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.

General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers Drugs; H.R. 5376, Inflation Reduction Act of 2022 (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Proposed Rebate Rule.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.

General issues related to Medicare and Medicaid, including Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy.

General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy.

Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy.

General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy.

Regulatory and legislative health care issues, including Alzheimers disease drug development; Drug Pricing; HR 5378 Drug Pricing Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA); Lower Costs, More Transparency Act.

Regulatory and legislative health care issues, including Alzheimers disease drug development Drug Pricing Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) including priority review vouchers; HR 5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM (Pharmacy Benefit Manager) Accountability Act; improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including Alzheimers disease drug development Drug Pricing Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) including priority review vouchers; HR 5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM (Pharmacy Benefit Manager) Accountability Act; improvements to the 340B drug discount program.

Regulatory and legislative health care issues, including Alzheimers disease drug development Drug Pricing Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) including priority review vouchers; HR 5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM (Pharmacy Benefit Manager) Accountability Act; improvements to the 340B drug discount program.

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; S. 4348/H.R.7667, Prescription Drug User Fee Act (PDUFA) reauthorization; S. 908/ H.R. 2139, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Issues related to pharmaceutical IP and supply chain; World Trade Organization waiver of Trade-Related Aspects of Intellectual Property Rights (TRIPS); and H.R.4521, AmericaCOMPETES Act of 2022.

Issues related to pharmaceutical IP and supply chain; World Trade Organization waiver of Trade-Related Aspects of Intellectual Property Rights (TRIPS); and H.R.4521, AmericaCOMPETES Act of 2022.

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Access to medicines in Medicare; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; Rebates and Medicare Part D - provisions related to the HHS-OIG Rebate Safe Harbor; Co-pay accumulators; Medicare Part D redesign proposals; Notice of Benefit and Payment Parameters; and Proposed Medicaid regulations; H.R. 5376, Inflation Reduction Act/FY2022 Budget Reconciliation.

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; Prescription Drug User Fee Act (PDUFA) reauthorization; The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; S. 4348/H.R.7667, Prescription Drug User Fee Act (PDUFA) reauthorization; S. 908/ H.R. 2139, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; S. 4348/H.R.7667, Prescription Drug User Fee Act (PDUFA) reauthorization; S. 908/ H.R. 2139, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; Prescription Drug User Fee Act (PDUFA) reauthorization; The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; S. 4348/H.R.7667, Prescription Drug User Fee Act (PDUFA) reauthorization; S. 908/ H.R. 2139, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; S. 4348/H.R.7667, Prescription Drug User Fee Act (PDUFA) reauthorization; S. 908/ H.R. 2139, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).

Regulatory and legislative health care issues: 340B program; Value-based drug contracting; Proposals related to drug pricing; Issues related to global pharmaceutical supply chain; Bayh-Dole march-in rights; Medicare Part D Negotiation/Non-interference repeal bills; Prescription Drug User Fee Act (PDUFA) reauthorization; The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act).